Provectus Pharmaceuticals

PVCT · OTC · United States

Share price · PVCT

$0.06-0.01 (-16.18%) 3M

no price since 18 Aug 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PVCT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 8 Apr 2026-12.3%
  2. 7 Apr 2026+14.0%
  3. 9 Feb 2026+15.8%
  4. 6 Feb 2026-9.5%
  5. 26 Jan 2026-13.8%

    Nothing announced by PVCT that day or the session before.

  6. 2 Jan 2026+14.3%
  7. 26 Nov 2025+18.5%

    Nothing announced by PVCT that day or the session before.

  8. 25 Nov 2025-19.4%

    Nothing announced by PVCT that day or the session before.

  9. 2 Oct 2025-13.6%

    Nothing announced by PVCT that day or the session before.

  10. 25 Sep 2025+31.3%

    Nothing announced by PVCT that day or the session before.

Share of unusual movement by asset

For each asset, the share of PVCT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
rose bengal disodiumNo recent activity
Phase 3
—Small molecule
Melanoma
Locally Advanced Cutaneous Melanoma
PH-10No recent activity
Phase 2
Photoactivated hydrogel (Rose Bengal disodium)Small molecule
Psoriasis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$0.2M—$1.3M-$0.9M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$0.1M$1.2M$1.0M-$0.4M operating cash flowreport ↗
2026-Q1$0$0.3M$0.2M$1.3M-$0.4M operating cash flowreport ↗
2025-Q3—$0.3M$0.1M$1.3M-$0.8M operating cash flowreport ↗
2025-Q2$0.1M$0.9M$0.4M$1.8M-$0.5M operating cash flowreport ↗
2025-Q1$0.3M$0.4M$0.4M$1.1M-$1.1M operating cash flowreport ↗
2024-Q3$0.1M$0.4M$0.2M$1.0M-$0.6M operating cash flowreport ↗
2024-Q2$0.3M$0.5M<$0.1M$0.8M-$0.8M operating cash flowreport ↗
2024-Q1$0.2M$0.6M<$0.1M$0.5M-$1.0M operating cash flowreport ↗
2023-Q3$0.1M$0.3M$0.4M$0.8M-$0.8M operating cash flowreport ↗
2023-Q2$0.2M$0.4M$0.2M$0.8M-$0.6M operating cash flowreport ↗
2023-Q1$0.2M$0.6M<$0.1M$0.8M-$0.6M operating cash flowreport ↗
2022-Q3$0.3M$0.6M$0.1M$0.7M-$0.8M operating cash flowreport ↗
2022-Q2$0.3M$0.8M$0.1M$1.1M-$0.9M operating cash flowreport ↗
2022-Q1$0.2M$0.7M$0.2M$1.0M-$0.6M operating cash flowreport ↗
2021-Q3—$0.6M$0.3M$1.1M-$0.7M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.3M$1.9M$0.3M$1.4M-$3.3M operating cash flowreport ↗

For fiscal year 2025, Provectus Biopharmaceuticals reported revenue of $0.34M, down 45.2% YoY, with R&D spend of $1.9M, down 5.0% YoY. Cash and equivalents stood at $0.25M, and the company reported a net loss of $5.43M with a quarterly net burn of $5.43M.

The 10-K narrative describes Provectus as a clinical-stage biotechnology company developing rose bengal sodium-based immunotherapies, with clinical programs including intratumoral PV-10 for oncology, topical PH-10 for dermatology, and PV-305 for ophthalmology. The company highlighted ongoing non-clinical work in oral oncology, hematology, wound healing, and animal health, as well as one new U.S. patent award and several international patent grants during 2025. Plans include initiating new early-stage trials for penile squamous cell carcinoma and FOLRINOX-refractory pancreatic ductal adenocarcinoma, and advancing a systemically administered PV-10 formulation toward an IND filing.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.6M$2.0M$0.3M$1.2M-$3.3M operating cash flowreport ↗
2023-FY$0.6M$1.8M$0.1M$0.8M-$2.6M operating cash flowreport ↗
2022-FY$1.0M$2.4M<$0.1M$0.9M-$3.0M operating cash flowreport ↗
2021-FY—$2.6M$0.7M$1.4M-$1.0M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-13Pershing Edward · director, CEO, 10% ownerOption exercise (derivative)———Form 4
2026-11-13Pershing Edward · director, CEO, 10% ownerOption exercise (derivative)11,328——Form 4
2026-11-06Pershing Edward · director, CEO, 10% ownerOption exercise (derivative)———Form 4
2026-11-06Pershing Edward · director, CEO, 10% ownerOption exercise (derivative)13,216——Form 4
2026-10-30Pershing Edward · director, CEO, 10% ownerOption exercise (derivative)———Form 4
2026-10-30Pershing Edward · director, CEO, 10% ownerOption exercise (derivative)24,544——Form 4
2026-10-23Pershing Edward · director, CEO, 10% ownerOption exercise (derivative)———Form 4
2026-10-23Pershing Edward · director, CEO, 10% ownerOption exercise (derivative)7,599——Form 4